Patritumab
- Generic Name
- Patritumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1262787-83-6
- Unique Ingredient Identifier
- 86780VJI1Q
- Background
Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Phase 1
Not yet recruiting
- Conditions
- Breast NeoplasmsBreast Cancer
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT06686394
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06596694
- Locations
- 🇨🇳
National Cheng Kung University Hospital-Clinical Trial Center ( Site 1502), Tainan, Taiwan
🇨🇳Taipei Veterans General Hospital ( Site 1501), Taipei, Taiwan
🇺🇸Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213), Miami Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath